Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IPO Year: 2010
Exchange: NASDAQ
Website: ironwoodpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $8.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 4/15/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/15/2025 | Buy → Hold | Jefferies | |
| 4/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 9/9/2024 | $5.00 | Market Perform | Leerink Partners |
| 8/8/2024 | $12.00 → $4.00 | Overweight → Equal Weight | CapitalOne |
| 1/17/2024 | $21.00 | Buy | Craig Hallum |
| 12/14/2023 | $20.00 | Overweight | Wells Fargo |
| 11/9/2023 | $21.00 | Buy | Jefferies |
| 9/28/2023 | $22.00 | Mkt Outperform | JMP Securities |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citizens JMP upgraded Ironwood Pharma from Mkt Perform to Mkt Outperform and set a new price target of $8.00
Wells Fargo downgraded Ironwood Pharma from Overweight to Equal Weight
Jefferies downgraded Ironwood Pharma from Buy to Hold
Citizens JMP downgraded Ironwood Pharma from Mkt Outperform to Mkt Perform
Leerink Partners initiated coverage of Ironwood Pharma with a rating of Market Perform and set a new price target of $5.00
CapitalOne downgraded Ironwood Pharma from Overweight to Equal Weight and set a new price target of $4.00 from $12.00 previously
Craig Hallum initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
Wells Fargo initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $20.00
Jefferies initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00
JMP Securities initiated coverage of Ironwood Pharma with a rating of Mkt Outperform and set a new price target of $22.00
8-K/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
DEFA14A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
DEF 14A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
Fastest customizable press release news feed in the world
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide,
– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved prescription therapy for pediatric FC – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC.
– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue of $107 million, GAAP net income of $41 million and adjusted EBITDA of $77 million in Q1 2026 – – On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 – – sNDA for LINZESS treatment of functional constipation (FC) in patients 2 to 5 years of age accepted and granted priority review by FDA; PDUFA date set for May 24th – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and com
– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence – – Additional presentations feature long-term apraglutide safety and tolerability data, new linaclotide data analyses across patient populations – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (T
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, May 7, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, May 21, 2026. To listen
– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) – – Linaclotide data presentations highlight efficacy and safety insights in IBS-C, CIC and pediatric FC – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professiona
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a ne
– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Wednesday, February 25, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Wedn
- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - - Ended Q4 2025 with greater than $200 million in cash and cash equivalents - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. "Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
Live Leadership Updates
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step down as senior vice president and chief financial officer, effective July 2, 2021, in order to pursue another leadership opportunity at a rare disease biotechnology company. Ms. Consylman’
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
– LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents – – Maintaining full year 2021 financial guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2021 results and recent business performance. "We are off to a solid start to the year, as LINZESS continued the strong momentum we saw in 2020," said Tom M
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent. “We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to adva
This live feed shows all institutional transactions in real time.
SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
Live finance-specific insights
– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue of $107 million, GAAP net income of $41 million and adjusted EBITDA of $77 million in Q1 2026 – – On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 – – sNDA for LINZESS treatment of functional constipation (FC) in patients 2 to 5 years of age accepted and granted priority review by FDA; PDUFA date set for May 24th – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and com
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, May 7, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, May 21, 2026. To listen
– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Wednesday, February 25, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Wedn
– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March
– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer
– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li
– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off